

Regorafenib GRID

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Regorafenib GRID

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Sarcoma

Therapeutic Indication: 3rd line after imatinib and sunitinib - patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib

Experimental Arm: Regorafenib + Best supportive care

Control Arm: Placebo plus best supportive care



